Aptose Biosciences Inc. logo
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
March 10, 2023 18:44 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Inc. logo
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
March 09, 2023 16:05 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences Inc. logo
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences Inc. logo
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
January 30, 2023 07:00 ET | Aptose Biosciences, Inc.
•  AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial•  New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient•  Aptose Elucidates Rationale for...
Aptose Biosciences Inc. logo
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
December 28, 2022 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences Inc. logo
Aptose Biosciences Establishes New At-The-Market Facility
December 12, 2022 06:15 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Inc. logo
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
December 11, 2022 09:00 ET | Aptose Biosciences, Inc.
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to...
Aptose Biosciences Inc. logo
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
December 07, 2022 16:05 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Inc. logo
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
November 14, 2022 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Biosciences Inc. logo
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
November 03, 2022 09:10 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...